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ABSTRACT
Objectives: To assess trends in prescribing practices
of antidiabetic agents and glycaemic control in patients
with type 2 diabetes mellitus (T2DM).
Design: Cross-sectional analysis using yearly clinical
data and antidiabetic treatments prescribed obtained
from an electronic population database.
Setting: Primary healthcare centres, including
the entire population attended by the Institut
Català de la Salut in Catalonia, Spain, from 2007 to
2013.
Participants: Patients aged 31–90 years with a
diagnosis of T2DM.
Results: The number of registered patients with
T2DM in the database was 257 072 in 2007,
increasing up to 343 969 in 2013. The proportion of
patients not pharmacologically treated decreased by
9.7% (95% CI −9.48% to −9.92%), while there was
an increase in the percentage of patients on
monotherapy (4.4% increase; 95% CI 4.16% to
4.64%), combination therapy (2.8% increase; 95% CI
2.58% to 3.02%), and insulin alone or in
combination (increasing 2.5%; 95% CI 2.2% to
2.8%). The use of metformin and dipeptidyl
peptidase-IV inhibitors increased gradually, while
sulfonylureas, glitazones and α-glucosidase
inhibitors decreased. The use of glinides remained
stable, and the use of glucagon-like peptide-1
receptor agonists was still marginal. Regarding
glycaemic control, there were no relevant differences
across years: mean glycated haemoglobin (HbA1c)
value was around 7.2%; the percentage of patients
reaching an HbA1c≤7% target ranged between
52.2% and 55.6%; and those attaining their
individualised target from 72.8% to 75.7%.
Conclusions: Although the proportion of patients
under pharmacological treatment increased
substantially over time and there was an increase in
the use of combination therapies, there have not
been relevant changes in glycaemic control during
the 2007–2013 period in Catalonia.
INTRODUCTION
Type 2 diabetes mellitus (T2DM) is a highly
prevalent chronic disease at risk of chronic
microvascular and macrovascular complica-
tions when glycaemic control is suboptimal.1
Although diet and lifestyle changes are ini-
tially effective, most patients will need an
oral glucose-lowering agent to better control
blood glucose levels, and most will eventually
need multiple therapies as the disease pro-
gresses.2 The pharmacological armamentar-
ium to treat hyperglycaemia in T2DM has
changed substantially over the past 20 years
with the development of new therapeutic
agents, such as insulin secretagogues (glini-
des), thiazolidinediones, incretins (glucagon-
like peptide-1 receptor agonists (GLP-1ra)
and dipeptidyl peptidase-IV inhibitors (DPP4i)),
sodium-glucose transporter-2 inhibitors, ﬁxed-
dose combinations, and also with the advent of
Strengths and limitations of this study
▪ The main strength of the study is the use of a
large outpatient database that is indicative of the
trends of general practitioners’ practices in a
real-life clinical setting.
▪ However, this was a retrospective study partici-
pant to errors in data recording or missing
values.
▪ We were not able to assess whether the change
in prescribed treatments over time was driven by
patients’ needs and characteristics (eg, prior low
tolerability or effectiveness), and we cannot
therefore claim a causal effect.
▪ We could not assess whether doses of pharma-
cological treatments were appropriately chosen,
and we did not consider data on prescriptions
within the same therapeutic class.
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insulin analogues.3 This, together with changing treat-
ment recommendations advocating for an intense gly-
caemic control in early stages of the disease,4 5 makes
drug choice increasingly challenging, and it has driven
substantial changes in current prescribing practices with
wide variations between countries depending on each
therapeutic class.6–17
General practice databases are a reliable and rich
source of information from the general population, and
therefore a valuable tool to study medical practice in the
community.18 In Catalonia, Spain, such an electronic
general practice database is available for researchers
(Information System for the Development of Research
in Primary Care (SIDIAP)), and it has been previously
used to conduct several observational studies to assess
different aspects of the natural history and treatment of
T2DM in our autonomous region.19–26
In the present study, we aimed to examine prescribing
patterns for antidiabetic treatment in primary care in
Catalonia between 2007 and 2013 using SIDIAP data,
and how changes impacted the degree of attained gly-
caemic control over time.
MATERIALS AND METHODS
Design
This was a cross-sectional, retrospective study using the
SIDIAP database, which started in 2006 and stores data
from electronic medical records. The database contains
anonymised longitudinal patient information obtained
from the electronic clinical records using speciﬁc soft-
ware (Electronic Clinical station in Primary Care, eCAP)
developed by the institution and used since 2001 by all of
the 274 primary care centres pertaining to the Catalan
Health Institute (ICS), which attends 80% of the total
population (about 5.835 million patients) in Catalonia.
Data extraction
Data from patients aged 31 to 90 years with a diagnosis of
T2DM (by means of the International Classiﬁcation of
Diseases, 10th Revision (ICD-10) codes E11 or E14) were
obtained from the SIDIAP database for the years 2007–
2013. Data were extracted for patients for each particular
year. As a dynamic database, new patients enter when a
new diagnosis of T2DM is recorded, and patients are with-
drawn when a death occurs or the patient moves to
another healthcare region not served by the Catalonian
Health Institute. Registered variables included: age;
gender; time since diagnosis; the presence of comorbid-
ities (ICD-10 codes); and the most recent value for each
year of body mass index (BMI) and mean glycated haemo-
globin (HbA1c). Before 1 January 2010, between 50% and
70% of laboratories in Spain expressed HbA1c values
using the Japanese Diabetes Society/Japanese Society for
Clinical Chemistry criteria ( JDS/JCC; normal range 3.9–
5.7%),27 and these values were not converted to the inter-
nationally deﬁned Diabetes Control and Complications
Trial/National Glycohemoglobin Standardization
Program (DCCT/NGSP) calibration criteria (normal
range 4–6%). All values from 1 January 2010 onwards were
expressed using DCCT/NGSP criteria.
The prescribed antidiabetic treatments for each patient
and year were extracted from prescription-invoicing and
pharmacy-invoicing data provided by the Catalan Health
Service (CatSalut), which are incorporated yearly into the
SIDIAP database. Glucose-lowering agents included the
use of insulin and non-insulin antidiabetic drugs (NIADs)
marketed in Spain during the study period, namely met-
formin, sulfonylureas, glinides, glitazones, DPP4i, GLP-1ra
and α-glucosidase inhibitors (AGI). The ﬁrst DPP4i mar-
keted in Spain was sitagliptin (2007) followed by vildaglip-
tin (2007), saxagliptin (2010) and linagliptin (2012). For
GLP-1ra, daily exenatide appeared in 2007, and liraglutide
in 2011. Treatment steps were categorised as non-
pharmacological treatment, an NIAD in monotherapy,
NIADs in combination (2 or more without insulin),
insulin alone or insulin in combination with NIADs.
Statistical analysis
Descriptive analyses by year are presented as mean and
SD for continuous variables, and percentages for cat-
egorical variables. Changes across the study period were
evaluated through the absolute overall increase and the
95% CIs using the normal approximation. We used
three different criteria for adequate glycaemic control:
mean HbA1c≤7%, as widely recommended and
accepted; HbA1c≤8%, as recommended by our institu-
tion during the study period (ICS);28 29 and individua-
lised goals based on age, duration of the disease, and
presence of serious complications or comorbidities, as
proposed by the Red de Grupos de Estudio de la
Diabetes en Atención Primaria de la Salud 2014
(Red-GDPS).30 All statistical calculations were performed
using StataCorp 2009 (Stata Statistical Software: Release
11. College Station, Texas, USA: StataCorp, LP).
RESULTS
Patients’ characteristics
The total number of registered patients with T2DM in
our database was 257 072 in 2007, increasing up to
343 969 in 2013 (a total increase of 86 897 cases) (table 1).
The patients’ mean age did not vary substantially over
the years (overall increase 1.20 years; 95% CI 1.14 to
1.26 years), and nor did the mean BMI or the number
of obese patients (overall decrease 0.08 kg/m2; 95% CI
−0.11 to −0.05 kg/m2; overall 0.043% decrease in obese
patients; 95% CI −0.12% to −0.74%), but we observed a
small progressive increase in the proportion of male
patients (overall increase 2.15%; 95% CI 1.90% to
2.40%), and also a gradual increase in the mean dur-
ation of the disease (overall increase 2.40 years; 95% CI
2.37 to 2.43 years).
Prescribing pattern of antidiabetic drugs
The proportion of patients not receiving antidiabetic
drugs decreased by 9.7% (95% CI −9.48% to −9.92%)
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from 2007 to 2013, while the percentage of patients
receiving pharmacological antidiabetic treatment was
71.9% in 2007, and this proportion increased annually
and was 81.6% in the last year of the study, showing an
overall 9.7% increase over the study period. The propor-
tion of patients receiving each type of therapy across the
time period 2007–2013 is shown in ﬁgure 1. The most
frequent prescription was an NIAD in monotherapy, the
use of which increased 4.4% (95% CI 4.16% to 4.64%)
from 2007 to 2013, followed by NIADs in combination
(increasing 2.8%; 95% CI 2.58% to 3.02%), and insulin
alone or in combination (increasing 2.5%; 95% CI 2.2%
to 2.8%). Among NIADs, the most frequently used
drugs were metformin and sulfonylureas, although the
prescription rate of metformin increased notably across
time (19.5%; 95% CI 19.25% to 19.75%), whereas it
decreased gradually in the case of sulfonylureas (8.20%;
95% CI −7.97% to −8.43%) (ﬁgure 2). As for the use of
the rest of the available options, only the prescription of
DPP4i increased substantially up to 13.2% in 2013 (95%
CI 13.09% to 13.31%), while the use of glitazones, gli-
nides, AGI and GLP-1ra remained low. Glitazones and
AGI prescriptions even decreased with time: glitazones
an overall 2.9% (95% CI −2.82% to −2.98%) and AGI
2.70% (95% CI −2.62% to −2.78%). Finally, glinides
and GLP-1ra only increased slightly over time: 0.8% in
the case of glinides (95% CI 0.69% to 0.91%) and 0.9%
in the case of GLP-1ra (95% CI 0.87% to 0.93%).
Evolution of the degree of glycaemic control
The mean standardised HbA1c value was around 7.2%,
with no clinically relevant differences across years (table 1).
Moreover, the proportion of patients attaining a gly-
caemic target of HbA1c≤7% ranged from 52.2% to
55.6% (overall change 0.29%; 95% CI −0.02% to
0.60%), and the ICS target ≤8% ranged from 77.8% to
79.6% (overall change 0.64%; 95% CI 0.39% to
21.42%), with no clinically relevant changes across years
(table 1). Moreover, the percentage of patients attaining
their individualised HbA1c target ranged increased by
only 1.15% (95% CI 0.88% to 1.42%) (table 1). Finally,
the analysis of the evolution of the attained glycaemic
control according to different HbA1c intervals also
showed that there were no remarkable changes among
years in any case (ﬁgure 3). Of note, the group of
patients who were less likely to achieve the correspond-
ing glycaemic target included those younger than
65 years, without comorbidities, and duration of
T2DM≤15 years (range 50.8–55.1%) (see online
supplementary table S1).
The evolution of the mean Hb1Ac levels according to
each step of treatment and duration of T2DM is shown
in ﬁgure 4 and online supplementary table S2.
Considering all antidiabetic treatments, there was a pro-
gressive worsening of HbA1c levels as the disease dur-
ation increased, but this worsening was in fact only
observed among patients treated with insulin alone or in
combination with NIADs. Conversely, glycaemic values
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in patients not pharmacologically treated or on NIADs
improved as T2DM duration increased, with no substan-
tial differences across the study period.
DISCUSSION
This cross-sectional descriptive study is, to the best of
our knowledge, the ﬁrst to assess trends in the prescrib-
ing practices of antidiabetic drugs in relation to the level
of attained glycaemic control between 2007 and 2013 in
a primary healthcare setting in Spain.
A gradual increase in the prescription of antidiabetic
agents has been previously reported in Spain16 17 and in
studies conducted worldwide throughout the same or
overlapping years as in our study.6–8 10–12 31 32 An increase
in the use of combinations of oral antidiabetic drugs
(OADs) has been consistently observed in several studies
from different countries,6 7 9 11 17 31 but the trends in its
use as monotherapy vary among reports, with some
describing an overall increase over time,11 13 32 and
others a progressive decrease.6 9 31 Moreover, while the
number of prescriptions of insulin in combination with
an OAD has been shown to increase with time,6 7 11 the
use of insulin alone has been reported to remain
stable,17 33 to decrease6 11 31 or even to increase.32
Differences between drug schemes and studies may be
attributable to health policy variations across countries,
local professional expertise, physician’s personal choice,
study setting (eg, hospital vs primary care or insurance
claims vs national database), or inclusion of both patients
with T1DM and T2DM in some cases.
Both an increase in the use of metformin and a
decrease in the use of sulfonylureas have been consist-
ently reported by other groups.6–9 11–13 15 17 31–33 This
decline could be related to the recent recommendation
of cautionary use in the elderly,34 their worse safety
proﬁle, associated weight gain, unclear role in reducing
long-term complications and/or to the availability of
safer new therapeutic options.5 Although a decrease in
glinides and AGIs use has been reported in Spain, Japan
Figure 2 Percentage of patients
having non-insulin antidiabetic
drug prescriptions (alone or in
combination). AGI, α-glucosidase
inhibitors; DPP4i, dipeptidyl
peptidase-IV inhibitors; GLP-1ra,
glucagon-like peptide-1 receptor
agonists; T2DM, type 2 diabetes
mellitus.
Figure 1 Percentage of patients
with T2DM at each step of
antidiabetic treatment. NIAD,
non-insulin antidiabetic drug;
T2DM, type 2 diabetes mellitus.
4 Mata-Cases M, et al. BMJ Open 2016;6:e012463. doi:10.1136/bmjopen-2016-012463
Open Access
group.bmj.com on May 18, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
and in the UK,11 15 17 33 in our study the number of gli-
nides prescriptions remained stable, which could be
explained by the fact that in spite of their risk of hypo-
glycaemia,5 they are the most used therapeutic class in
patients with chronic kidney disease.25 The decrease in
AGIs might be explained by the high frequency of
gastrointestinal side effects that led to the recommenda-
tion to only use them in people unable to use other oral
glucose-lowering medications.35 The decrease in the use
of glitazones has been consistently documented in
several studies that included data after 2007,8 9 11–13
15 17 31–33 when the ﬁrst regulatory warnings and the
results of a meta-analysis alerted clinicians to cardiovas-
cular risk associated with rosiglitazone,36 37 and to a risk
of bladder cancer with pioglitazone in 2011.38 Both side
effects have been recently ruled out,37 39 but the inﬂu-
ence of these alarms, together with weight gain, the risk
of heart failure and the increased risk of bone fractures
in women observed with this class of drugs, has limited
its use. The marginal use of GLP-1ra in our study is
similar to that of a recent study conducted in the UK,15
but in contrast with a substantial increase documented
in another region of Spain,17 Ireland and the USA.9 13
The administrative restrictions and negative economic
incentives of our institution (ICS) for the prescription of
GLP-1ar may have contributed to the limited use of this
therapeutic class. Finally, DPP4i the class of newly devel-
oped NIADs with the greatest increase in use, which is
in agreement with other reports conducted world-
wide.9 11–13 17 31–33 This rapid adoption, mainly as an
alternative to sulfonylureas, may respond to the lower
risk of hypoglycaemia, its neutral effects on body weight
and also the greater convenience of an oral treatment
instead of the need of injections for GLP-1ar or
insulin.40 In summary, although a plethora of hypogly-
caemic agents are currently available with a substantially
comparable effect in terms of glycaemic control, the
physician’s choice should be personalised based on
patient’s characteristics such as age, risk factors and
comorbidities.
When we assessed the attained glycaemic control based
on the treatment step, we found that patients on NIADs
in combination or on insulin with or without an NIAD
were the ones with the highest HbA1c levels. This is in
line with the results of several studies showing a delay in
treatment intensiﬁcation in patients already on combin-
ation therapies whose control of blood glucose remained
or became inadequate.35 41 Moreover, we found that
about half of the patients had HbA1c levels ≤7% as
recommended by clinical guidelines, about 80% below
the 8% recommended by our institution (ICS), and
about 75% below the individualised goal recommended
by the Red-GDPS. Our ﬁgures are slightly worse than the
ones reported by a study conducted in the Basque
country in Spain for patients achieving HbA1c levels
≤7% (about 64.1% of them), but similar to their 85.5%
of patients achieving a ≤8% target.42 Finally, and con-
ﬁrming previous analyses, the subgroup with the highest
proportion of patients attaining appropriate individua-
lised glycaemic control was the one of patients older than
75 years,23 while patients younger than 65 years without
comorbidities or serious complications and T2DM dur-
ation ≤15 years were less likely to achieve the correspond-
ing individualised glycaemic control target. This could be
explained by a higher proportion of obesity among
younger patients, a longer survival among adequately
controlled older patients, or by an easier to reach gly-
caemic goal in the elderly (≤8% vs ≤7%). More import-
antly, our results conﬁrm that an individualised
therapeutic approach considerably increases the chances
of attaining adequate glycaemic control and provides
effective T2DM care.43 However, one of the most striking
Figure 3 Percentage of patients
achieving glycaemic control
according to HbA1c intervals.
HbA1c, glycated haemoglobin;
T2DM, type 2 diabetes mellitus.
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ﬁndings of our study was that there were no relevant
changes across years, meaning that in spite of the overall
observed gradual increase in pharmacological treatments
along the study there was no obvious trend towards an
increase in the proportion of patients with an adequate
HbA1c target whatever the used cut-off, and the mean
HbA1c values did not signiﬁcantly change over time
regardless of the treatment step. There are few reports on
how the evolution in the prescription pattern of antidia-
betic drugs affects the level of attained glycaemic control,
but our results are in contrast with a study conducted in
Japan showing that the rate of patients achieving the
≤7% goal signiﬁcantly improved together with the pro-
gressive increase in the proportion of pharmacological
treatments.11 However, a very recent study conducted in
Canada reported that the mean HbA1c values in older
patients even increased slightly over a 5-year period in
spite of the overall increase in the use of antidiabetic
treatment.14 Our results seriously question the ICS
threshold to maintain HbA1c levels ≤8% for all patients,
giving general practitioners ﬁnancial incentives if this
goal is attained, without taking into account age, diabetes
duration or the presence of comorbidities. This threshold
was established to avoid overtreatment—especially in the
elderly—but can be counterproductive in younger
patients. Certainly, about 25% of patients had HbA1c
between 7.1% and 8%, and were therefore at
potential risk of suboptimal management or undertreat-
ment until they reached this value, especially in
people aged under 65 years. Thus, this institutional
policy potentially contributes to therapeutic inertia,
deﬁned as a delay in treatment intensiﬁcation among
patients with poor glycaemic control. Clinical inertia has
been documented in primary care settings,44 45 and a
study conducted in Catalonia in 2007 in a sample of 2783
patients with T2DM reported that therapeutic inertia was
present in 33.2% of cases, and treatment intensiﬁcation
was implemented in patients with a mean HbA1c of
8.4%,41 which is far above the 8% threshold established
by the institution. On the other hand, most family
physicians ﬁnd that patients treated with an NIAD com-
bination but needing intensiﬁcation with insulin or
GLP-1ar, and those already on insulin needing optimisa-
tion with multiple insulin doses or the addition of a
GLP-1ar, are difﬁcult to manage or they have reasonable
safety concerns. In these cases, clinical inertia is a major
factor that contributes to inadequate glycaemic control
in the long term.
Figure 4 Evolution of mean HbA1c according to the different steps of antidiabetic treatment and T2DM duration. HbA1c,
glycated haemoglobin; NIAD, non-insulin antidiabetic drug; T2DM, type 2 diabetes mellitus.
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Our results show a global negative effect of T2DM dur-
ation on glycaemic control that did not change substan-
tially across the study period. A progressive worsening of
mean Hb1Ac values within each sequential evaluation
might be expected because the proportion of patients
with a disease duration >10 years increased, but this
could have been counteracted by an intensiﬁed manage-
ment in all treatment steps, eventually leading to steady
mean HbA1c levels along the study. This is a possible
explanation if we take into account that patients in the
lowest treatment steps (ie, no drugs, and NIADs in
monotherapy or combined) and with a disease duration
>10 years had lower HbA1c values than those with a
disease duration lower than <2 years, as those on poor
glycaemic control were probably switched to the next
superior treatment step. In contrast, glycaemic control
among patients on insulin (alone or in combination)
worsened as the duration of disease increased, probably
because they are at the last treatment step and only
intensive management with multiple insulin doses under
endocrinologist supervision may improve control.
This study has strengths and limitations worth men-
tioning. The main strength is that we used a large out-
patient database that, although not completely
representative of other areas of Spain, is indicative of
the trends of general practitioners’ practices in a real-life
clinical setting. However, this was a retrospective study
subject to errors in data recording. For instance, the per-
centage of missing values for HbA1c was 35% in 2007
and decreased to 25% in 2013, although this would
apply equally to all study periods, therefore not affecting
the conclusions of the study. Moreover, we were not able
to assess whether the change in prescribed treatments
over time was driven by patients’ needs and character-
istics (eg, prior low tolerability or effectiveness), and we
cannot therefore claim a causal effect. Finally, we could
not assess whether doses were appropriately chosen, and
we did not consider data on prescriptions within the
same therapeutic class.
CONCLUSIONS
Although the intensity of pharmacological antidiabetic
treatment of T2DM increased substantially during 2007–
2013 in Catalonia, there was no evidence that this was
accompanied by a positive change in the degree of gly-
caemic control. This reveals shortcomings in the primary
healthcare system that could be tackled through more
intensive educational programmes for physicians oriented
to the individualisation of glycaemic goals and prioritising
more intensive treatments in younger patients.
Author affiliations
1DAP-Cat group. Unitat de Suport a la Recerca Barcelona Ciutat, Institut
Universitari d’Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol),
Barcelona, Spain
2Centro de Investigación Biomédica en Red de Diabetes y Enfermedades
Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III (ISCIII),
Spain
3Primary Health Care Center La Mina, Gerència d’Àmbit d’Atenció Primària
Barcelona Ciutat, Institut Català de la Salut, Sant Adrià de Besòs, Spain
4Primary Health Care Center Raval Sud, Gerència d’Àmbit d’Atenció Primària
Barcelona Ciutat, Institut Català de la Salut, Barcelona, Spain
5Universitat Internacional de Catalunya, Epidemiologia i Salut Pública, Sant
Cugat, Spain
6Department of Endocrinology & Nutrition, Health Sciences Research Institute
& Hospital Universitari Germans Trias i Pujol, Badalona, Spain
Acknowledgements The authors acknowledge Mònica Gratacòs and Amanda
Prowse for providing support in manuscript preparation and editing. CIBER of
Diabetes and Associated Metabolic Diseases (CIBERDEM) is an initiative from
Instituto de Salud Carlos III.
Contributors MM-C and JF-N wrote the manuscript and contributed equally
to this study. JR managed the database, performed the statistical analyses
and contributed to the discussion. JF-N, MM-C and DM conceived the study,
participated in the study design, contributed to data cleaning, analysis and
interpretation, reviewed/edited the manuscript and contributed to the
discussion. MM-C had full access to all data in the study and takes
responsibility for the integrity of data and the accuracy of the data analysis.
Funding This study was funded by Institut Universitari d’Investigació en
Atenció Primària Jordi Gol (IDIAP Jordi Gol), and an unrestricted grant
provided by Astra Zeneca.
Disclaimer The funding sources had no role in the design and conduct of
the study; collection, management, analysis and interpretation of the data; or
preparation, review or approval of the manuscript.
Competing interests None declared.
Ethics approval Ethics Committee of the Primary Health Care University
Research Institute (IDIAP) Jordi Gol.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement No additional data are available.
Open Access This is an Open Access article distributed in accordance with
the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license,
which permits others to distribute, remix, adapt, build upon this work non-
commercially, and license their derivative works on different terms, provided
the original work is properly cited and the use is non-commercial. See: http://
creativecommons.org/licenses/by-nc/4.0/
REFERENCES
1. International Diabetes Federation. IDF Diabetes Atlas. 6th edn.
Brussels, Belgium: International Diabetes Federation, 2013.
2. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet,
sulfonylurea, metformin, or insulin in patients with type 2 diabetes
mellitus: progressive requirement for multiple therapies (UKPDS 49).
UK Prospective Diabetes Study (UKPDS) Group. JAMA
1999;281:2005–12.
3. Bailey CJ. The current drug treatment landscape for diabetes and
perspectives for the future. Clin Pharmacol Ther 2015;98:170–84.
4. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of
intensive glucose control in type 2 diabetes. N Engl J Med
2008;359:1577–89.
5. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of
hyperglycemia in type 2 diabetes, 2015: a patient-centered
approach: update to a position statement of the American Diabetes
Association and the European Association for the Study of Diabetes.
Diabetes Care 2015;38:140–9.
6. Baviera M, Monesi L, Marzona I, et al. Trends in drug prescriptions
to diabetic patients from 2000 to 2008 in Italy’s Lombardy region: a
large population-based study. Diabetes Res Clin Pract
2011;93:123–30.
7. Chang CH, Jiang YD, Chung CH, et al. National trends in
anti-diabetic treatment in Taiwan, 2000–2009. J Formos Med Assoc
2012;111:617–24.
8. Leal I, Romio SA, Schuemie M, et al. Prescribing pattern of glucose
lowering drugs in the United Kingdom in the last decade: a focus on
the effects of safety warnings about rosiglitazone. Br J Clin
Pharmacol 2013;75:861–8.
Mata-Cases M, et al. BMJ Open 2016;6:e012463. doi:10.1136/bmjopen-2016-012463 7
Open Access
group.bmj.com on May 18, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
9. Turner LW, Nartey D, Stafford RS, et al. Ambulatory treatment of
type 2 diabetes in the U.S., 1997–2012. Diabetes Care
2014;37:985–92.
10. Strøm H, Selmer R, Birkeland KI, et al. No increase in new users of
blood glucose-lowering drugs in Norway 2006–2011: a nationwide
prescription database study. BMC Public Health 2014;14:520.
11. Oishi M, Yamazaki K, Okuguchi F, et al. Changes in oral antidiabetic
prescriptions and improved glycemic control during the years 2002–
2011 in Japan ( JDDM32). J Diabetes Investig 2014;5:581–7.
12. Hampp C, Borders-Hemphill V, Moeny DG, et al. Use of antidiabetic
drugs in the U.S., 2003–2012. Diabetes Care 2014;37:1367–74.
13. Zaharan NL, Williams D, Bennett K. Prescribing of antidiabetic
therapies in Ireland: 10-year trends 2003–2012. Ir J Med Sci
2014;183:311–18.
14. Clemens KK, Liu K, Shariff S, et al. Secular trends in
antihyperglycaemic medication prescriptions in older adults with
diabetes and chronic kidney disease: 2004–2013. Diabetes Obes
Metab 2016;18:607–14.
15. Sharma M, Nazareth I, Petersen I. Trends in incidence, prevalence
and prescribing in type 2 diabetes mellitus between 2000 and 2013
in primary care: a retrospective cohort study. BMJ Open 2016;6:
e010210.
16. Pornet C, Bourdel-Marchasson I, Lecomte P, et al. Trends in the
quality of care for elderly people with type 2 diabetes: the need for
improvements in safety and quality (the 2001 and 2007 ENTRED
surveys). Diabetes Metab 2011;37:152–61.
17. Mancera-Romero J, Hormigo-Pozo A, Fernández-Arquero J, et al.
[Use of glucose-lowering drugs in a primary care setting in Malaga
during the years 2008–2012]. Semergen 2014;40:4–11.
18. Lawrenson R, Williams T, Farmer R. Clinical information for
research; the use of general practice databases. J Public Health
Med 1999;21:299–304.
19. Vinagre I, Mata-Cases M, Hermosilla E, et al. Control of glycemia
and cardiovascular risk factors in patients with type 2 diabetes in
primary care in Catalonia (Spain). Diabetes Care 2012;35:774–9.
20. Mata-Cases M, Mauricio D, Vinagre I, et al. Treatment of
hyperglycaemia in type 2 diabetic patients in a primary care
population database in a Mediterranean area (Catalonia, Spain).
J Diabetes Metab 2014;5:338.
21. Franch-Nadal J, Mata-Cases M, Vinagre I, et al. Differences in the
cardiometabolic control in type 2 diabetes according to gender and
the presence of cardiovascular disease: results from the eControl
study. Int J Endocrinol 2014;2014:131709.
22. Rodriguez-Poncelas A, Miravet-Jiménez S, Casellas A, et al.
Prevalence of diabetic retinopathy in individuals with type 2 diabetes
who had recorded diabetic retinopathy from retinal photographs in
Catalonia (Spain). Br J Ophthalmol 2015;99:1628–33.
23. Barrot-de la Puente J, Mata-Cases M, Franch-Nadal J, et al. Older
type 2 diabetic patients are more likely to achieve glycaemic and
cardiovascular risk factors targets than younger patients: analysis of
a primary care database. Int J Clin Pract 2015;69:1486–95.
24. Mata-Cases M, Casajuana M, Franch-Nadal J, et al. Direct medical
costs attributable to type 2 diabetes mellitus: a population-based
study in Catalonia, Spain. Eur J Health Econ 2015. Published Online
First: 5 Nov 2015. doi:10.1007/s10198-015-0742-5
25. Ruiz-Tamayo I, Franch-Nadal J, Mata-Cases M, et al. Noninsulin
antidiabetic drugs for patients with type 2 diabetes mellitus: are we
respecting their contraindications? J Diabetes Res
2016;2016:7502489.
26. Mata-Cases M, Mauricio D, Franch-Nadal J. Clinical characteristics
of type 2 diabetic patients on basal insulin therapy with adequate
fasting glucose control that do not achieve glycated hemoglobin
targets. J Diabetes 2016. Published Online First: 8 Jan 2016.
doi:10.1111/1753-0407.12373.
27. Goberna R, Aguilar-Diosdado M, Santos-Rey K, et al. Consensus
document for the harmonization of HbA1c results in Spain. Av
Diabetol 2009;25:35–7.
28. Mata-Cases M, Cos-Claramunt FX, Morros R, et al. Abordatge de la
diabetis mellitus tipus 2 [online]. 2010; Guies de pràctica clínica,
num 15. http://www.gencat.cat/ics/professionals/guies/diabetis/
diabetis.htm (accessed 27 Jun 2014).
29. Avilés F, MB L, Coma Redon E, et al. Sistema de Información de los
Servicios de Atención Primaria (SISAP). La experiencia 2006-2009
del Institut Català de la Salut (ICS). RISAI 2010;2:1–17.
30. Alemán JJ, Artola S, Franch J, et al. Recomendaciones para el
tratamiento de la diabetes mellitus tipo 2: control glucémico.
Diabetes Práctica 2014;5:1–48.
31. Clemens KK, Shariff S, Liu K, et al. Trends in antihyperglycemic
medication prescriptions and hypoglycemia in older adults: 2002–
2013. PLoS ONE 2015;10:e0137596.
32. Rafaniello C, Arcoraci V, Ferrajolo C, et al. Trends in the prescription
of antidiabetic medications from 2009 to 2012 in a general practice
of Southern Italy: a population-based study. Diabetes Res Clin Pract
2015;108:157–63.
33. Kohro T, Yamazaki T, Sato H, et al. Trends in antidiabetic prescription
patterns in Japan from 2005 to 2011. Int Heart J 2013;54:93–7.
34. Sinclair AJ, Paolisso G, Castro M, et al., European Diabetes
Working Party for Older People. European Diabetes Working Party
for Older People 2011 clinical guidelines for type 2 diabetes mellitus.
Executive summary. Diabetes Metab 2011;37(Suppl 3):S27–38.
35. NICE (National Institute for Health and Clinical Excellence). Clinical
guideline CG87. Type 2 diabetes: the management of type 2
diabetes. Last updated December 2014. http://guidance.nice.org.uk/
CG87/NiceGuidance/pdf/English
36. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial
infarction and death from cardiovascular causes. N Engl J Med
2007;356:2457–71.
37. Swinnen SG, Hoekstra JB, DeVries JH. Insulin therapy for type 2
diabetes. Diabetes Care 2009;32(Suppl 2):S253–9.
38. Lewis JD, Ferrara A, Peng T, et al. Risk of bladder cancer among
diabetic patients treated with pioglitazone: interim report of a
longitudinal cohort study. Diabetes Care 2011;34:916–22.
39. Ryder RE. Pioglitazone has a dubious bladder cancer risk but an
undoubted cardiovascular benefit. Diabet Med 2015;32:305–13.
40. Karagiannis T, Paschos P, Paletas K, et al. Dipeptidyl peptidase-4
inhibitors for treatment of type 2 diabetes mellitus in the clinical
setting: systematic review and meta-analysis. BMJ 2012;344:e1369.
41. Mata-Cases M, Benito-Badorrey B, Roura-Olmeda P, et al. Clinical
inertia in the treatment of hyperglycemia in type 2 diabetes patients
in primary care. Curr Med Res Opin 2013;29:1495–502.
42. Alonso-Morán E, Orueta JF, Esteban JIF, et al. Prevalence and
quality of care indicators of type 2 diabetes in the population of the
Basque Country (Spain). Av Diabetol 2015;31:72–9.
43. Subramanian S, Hirsch IB. Personalized diabetes management:
moving from algorithmic to individualized therapy. Diabetes Spectr
2014;27:87–91.
44. Khunti K, Wolden ML, Thorsted BL, et al. Clinical inertia in people
with type 2 diabetes: a retrospective cohort study of more than
80,000 people. Diabetes Care 2013;36:3411–17.
45. Khunti K, Nikolajsen A, Thorsted BL, et al. Clinical inertia with regard
to intensifying therapy in people with type 2 diabetes treated with
basal insulin. Diabetes Obes Metab 2016;18:401–9.
8 Mata-Cases M, et al. BMJ Open 2016;6:e012463. doi:10.1136/bmjopen-2016-012463
Open Access
group.bmj.com on May 18, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
2013 in Catalonia: a population-based study
−with type 2 diabetes mellitus during 2007
 trends in primary care centres in patients
 Glycaemic control and antidiabetic treatment
Manel Mata-Cases, Josep Franch-Nadal, Jordi Real and Dídac Mauricio
doi: 10.1136/bmjopen-2016-012463
2016 6: BMJ Open 
 http://bmjopen.bmj.com/content/6/10/e012463
Updated information and services can be found at: 
These include:
References
 #BIBLhttp://bmjopen.bmj.com/content/6/10/e012463
This article cites 40 articles, 12 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by-nc/4.0/non-commercial. See: 
provided the original work is properly cited and the use is
non-commercially, and license their derivative works on different terms, 
permits others to distribute, remix, adapt, build upon this work
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
This is an Open Access article distributed in accordance with the Creative
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (430)Pharmacology and therapeutics
 (379)Diabetes and Endocrinology
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on May 18, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
